Access cutting-edge preterm birth treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Access preterm birth specialists in Philadelphia at no cost
This study follows strict safety protocols and ethical guidelines
All study-related preterm birth treatment provided free
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
Sponsor: The George Washington University Biostatistics Center
Check if you qualify for this preterm birth clinical trial in Philadelphia, PA
If you're searching for preterm birth treatment options in Philadelphia, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced preterm birth specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.